On December 4, 2019, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing additional positive interim safety and efficacy data from one of the Company\’s two ongoing open label, single arm Phase 1/2 studies of Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (\”AML\”).

A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 Press Release dated December 4, 2019

Moleculin Biotech, Inc. Exhibit
EX-99.1 2 exh991-pressrelease180coho.htm EXHIBIT 99.1 Exhibit Exhibit 99.1   Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid LeukemiaNo evidence of cardiotoxicity to date; 40% of 10 patients dosed at 120 mg/m2 demonstrate efficacy; trial progresses in Europe to 210 mg/m2 HOUSTON,…
To view the full exhibit click here

About MOLECULIN BIOTECH, INC. (NASDAQ:MBRX)

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of September 30, 2016, it had not generated any revenue from its operations.